Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Magnitude Of Effect, Not Survival, Is Key To Approval For Oncologic Nexavar

Executive Summary

Sponsors of oncology agents should select endpoints where a drug is likely to have a "magnitude of effect" instead of focusing on survival, FDA said following its Dec. 20 approval of Bayer/Onyx' kidney cancer therapy Nexavar (sorafenib)

You may also be interested in...



FDA Needs To Put Meaning Behind “Clinically Meaningful,” Lipicky Says

FDA's increasing requirements for clinical meaningfulness in efficacy measures make it more difficult to predict the agency's regulatory actions, former division director Ray Lipicky says

FDA Needs To Put Meaning Behind “Clinically Meaningful,” Lipicky Says

FDA's increasing requirements for clinical meaningfulness in efficacy measures make it more difficult to predict the agency's regulatory actions, former division director Ray Lipicky says

Oncologic Accelerated Approval Best Based On Pivotal Trial Interim Analysis

FDA is encouraging sponsors to use data from an interim analysis of an ongoing pivotal trial to support accelerated approval of cancer products, rather than relying on separate postmarketing studies

Related Content

UsernamePublicRestriction

Register

OM009724

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel